4/A: ATOS CEO Amends RSU Grant, Boosts Equity Holdings

ATOSSA THERAPEUTICS CEO Steven C. Quay amended a Form 4 filing to correct the number of restricted stock units acquired, alongside new stock option grants.

Summary

• Steven C. Quay, President & CEO and Director of ATOSSA THERAPEUTICS, INC. (ATOS), filed an amended Form 4 to correct an administrative error regarding the number of Restricted Stock Units (RSUs) acquired.
• The amendment clarifies that 331,674 RSUs were acquired on January 20, 2026, not the previously reported amount.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and will vest one year from the transaction date.
• Additionally, Mr. Quay acquired 950,000 stock options on January 20, 2026, with an exercise price of $0.603, which was the closing stock price on that date.
• These stock options will vest on a quarterly basis over 24 months following January 20, 2026, contingent on Mr. Quay's continued service.
• Following these transactions, Mr. Quay directly beneficially owns 345,572 shares of Common Stock and indirectly owns 22,254 shares through Ensisheim Partners, LLC.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects continued insider confidence and aligns the CEO's financial interests with long-term shareholder value, despite being an administrative correction.

Positives

• The acquisition of 331,674 Restricted Stock Units (RSUs) and 950,000 stock options by the President & CEO aligns management's interests with those of shareholders.
• The vesting schedules for both RSUs (one year) and stock options (quarterly over 24 months) incentivize long-term commitment and performance from the CEO.

Future Outlook

The vesting schedules for the acquired RSUs and stock options indicate an expectation of continued service from the President & CEO for at least one to two years, aligning his future compensation with the company's long-term performance.

Management Comments

• The filing itself, through the acquisition of equity, demonstrates management's commitment to the company's future, with the CEO's compensation tied to stock performance and continued service.

Industry Context

StockSavvy.ai notes that executive equity grants, such as RSUs and stock options, are standard practice in the biotechnology and pharmaceutical industries. These grants are designed to align the interests of key executives with those of shareholders, particularly in companies like Atossa Therapeutics, which are often in development stages and rely on long-term value creation.

Comparison to Industry Standards

• The grant of RSUs and stock options to a CEO is a common compensation strategy, comparable to practices at other small to mid-cap biotech firms, where equity-based incentives are crucial for attracting and retaining top talent.
• The vesting schedules (one year for RSUs, quarterly over 24 months for options) are typical for executive compensation packages, aiming to ensure sustained commitment rather than short-term gains.

Related Party Transactions

• Steven C. Quay indirectly owns 22,254 shares of Common Stock through Ensisheim Partners, LLC, which is wholly owned by Mr. Quay and Dr. Shu-Chih Chen. Mr. Quay disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The increased equity ownership and long-term vesting schedules for the CEO's compensation align his interests with those of shareholders, potentially fostering greater commitment to long-term value creation.
• Employees: The CEO's continued commitment, as incentivized by these grants, can provide stability and strategic direction for employees.

Next Steps

• The RSUs will vest one year from January 20, 2026.
• The stock options will vest quarterly over 24 months following January 20, 2026, subject to continued service.

Key Dates

Recommendation

While insider acquisition of equity is generally a positive signal, this Form 4/A primarily corrects an administrative error and details standard executive compensation. It doesn't introduce new fundamental information that would warrant a strong buy or sell recommendation, but it reinforces a 'hold' stance due to the alignment of management interests with shareholders.

Keywords

ATOSSA THERAPEUTICS, ATOS, Steven C. Quay, Restricted Stock Units, RSUs, Stock Options, Insider Trading, Beneficial Ownership, Executive Compensation, Form 4/A, SEC Filing